Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Fabric Protocol Fabric Protocol +18.73%
#4 Cysic Cysic +17.50%
#5 Bedrock Bedrock +10.70%
#6 Cap Cap +8.99%
#7 stake.link stake.link +6.21%
#8 Perle Perle +5.03%
#9 Pons Pons +4.86%
#10 Test Test +4.23%
Coin of the day
EXOD EXOD
Settings
Language
ENGLISH
Currency
USD
Theme
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Rank in Stocks #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Share Price
$0.1
Last synced: 2024-06-18
Market Cap
$1.31M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Pascal Biosciences Inc. (PSCBF)

Category

Healthcare
Operating Margin for Pascal Biosciences Inc. (PSCBF)
Operating Margin as of August 2026 TTM: -133.68%
According to Pascal Biosciences Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is -133.68%. At the end of 2022 the company had an Operating Margin of 0.00%.
Operating Margin history for Pascal Biosciences Inc. from 2019 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) -133.68% 0.00%
2023 -133.68% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.97% -100.29%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.22%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
0.00% -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
31.23% -100.23%
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.